Physician profile
Christopher J Goff
NPI 1740415124
$5,394.38
in general payments reported to CMS, 2019-2025
28 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $236 · 2021: $659 · 2022: $328 · 2023: $1,019 · 2024: $2,207 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,991 · Food and Beverage: $1,713 · Consulting Fee: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,990.78 |
| Food and Beverage | $1,713.00 |
| Consulting Fee | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,646.79 | 2024 | Fusion, Stealthstation S8 Platform, Pteye Parathyroid Detection System |
| Inspire Medical Systems, INC. | $1,476.37 | 2023-2025 | Inspire |
| Intersect Ent, INC. | $484.94 | 2019-2021 | |
| Stryker Corporation | $353.57 | 2019-2022 | |
| Optinose US, INC. | $298.35 | 2020-2025 | |
| Livanova USA, INC. | $137.54 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $115.69 | 2020-2022 | |
| Glaxosmithkline, LLC. | $109.52 | 2019-2025 | Nucala |
| Acclarent, INC | $78.53 | 2020-2023 | Acclarent Aera, Trudi Nav Cable, Relieva Tract |
| Alk-Abello, INC | $67.64 | 2021-2022 | |
| Aerin Medical INC. | $65.84 | 2021-2023 | |
| Genzyme Corporation | $64.59 | 2020-2024 | |
| Argenx US, INC. | $58.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.54 | 2019-2022 | |
| Integra Lifesciences Corporation | $46.33 | 2024-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $43.08 | 2024 | |
| Ucb, INC. | $41.44 | 2024 | Zilbrysq |
| Pacira Pharmaceuticals Incorporated | $40.94 | 2025 | Exparel |
| Smith+Nephew, INC. | $32.76 | 2024 | Coblation |
| Hikma Pharmaceuticals USA | $32.31 | 2024-2025 | Ryaltris |
| Acera Surgical, INC. | $26.95 | 2025 | Restrata Wound Matrix |
| Phathom Pharmaceuticals, INC. | $22.96 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $21.04 | 2022 | |
| Csl Behring | $20.75 | 2020 | |
| Paratek Pharmaceuticals, INC. | $20.00 | 2025 | Xhance |
| Avion Pharmaceuticals | $17.63 | 2021 | |
| Eisai INC. | $14.28 | 2020 | |
| Ambu INC. | $8.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Goff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.